Gami­da Cell makes more staff cuts and re­struc­tures as it fo­cus­es on po­ten­tial drug launch

Gami­da Cell is mak­ing some re­struc­tur­ing moves as it pre­pares for the po­ten­tial ap­proval of its lead drug.

In Gami­da Cell’s 2022 year-end re­port, the cell ther­a­py biotech said it will im­ple­ment a “strate­gic re­struc­tur­ing” to fo­cus on the launch of omidu­bi­cel, a stem cell-based can­di­date for bone mar­row trans­plants, if it gets the FDA thumbs-up. But it will have more lim­it­ed in­vest­ment and a slow­er ramp-up to man­age fi­nances.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER